Alise K Murray1, Rose B McGee1, Roya M Mostafavi1, Xiaoqing Wang2, Zhaohua Lu2, Jessica M Valdez3, Michael A Terao4, Kim E Nichols1. 1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 2. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA. 3. Department of Pediatrics, University of New Mexico, Albuquerque, NM, USA. 4. Department of Pediatrics, Division of Pediatric Hematology and Oncology, Medstar Georgetown University Hospital, Washington, DC, USA.
Abstract
BACKGROUND: With the advent of next generation sequencing, tumor and germline genomic testing are increasingly being used in the management of pediatric cancer patients. Despite this increase in testing, many pediatric hematology-oncology (PHO) providers are not confident interpreting or utilizing tumor or germline genomic results to care for their patients. METHODS: We developed and delivered a needs assessment survey to PHO program directors, attendings, and fellows in the United States to understand this deficiency, gather data on existing cancer genomics educational initiatives, and query preferences for creating a future curriculum. RESULTS: The survey includes 31 (41%) of 74 invited PHO program directors, 110 (11%) of 1032 invited attendings, and 79 fellows. The majority of attending physicians and fellows responding to the survey agree that understanding tumor (95% attending physicians; 95% fellows) and germline (86% attending physicians; 94% fellows) genomic information is essential for their practice. However, only 9 of 31 (29%) responding programs report that they have an existing cancer genomics curriculum. Most program directors indicated that the ideal genomics curriculum would occur during the first year of fellowship and incorporate direct patient care, online modules, and problem-based learning. Attending physicians and fellows identified that addressing indications for ordering tumor and germline genomic testing, counseling about the risks and benefits of such testing, and interpreting and individualizing clinical management based on tumor and germline results should be included in a future curriculum. CONCLUSION: The results of this study reveal a great need to develop a curriculum that can be offered across PHO fellowship programs to expand knowledge in the area of cancer genomics.
BACKGROUND: With the advent of next generation sequencing, tumor and germline genomic testing are increasingly being used in the management of pediatric cancerpatients. Despite this increase in testing, many pediatric hematology-oncology (PHO) providers are not confident interpreting or utilizing tumor or germline genomic results to care for their patients. METHODS: We developed and delivered a needs assessment survey to PHO program directors, attendings, and fellows in the United States to understand this deficiency, gather data on existing cancer genomics educational initiatives, and query preferences for creating a future curriculum. RESULTS: The survey includes 31 (41%) of 74 invited PHO program directors, 110 (11%) of 1032 invited attendings, and 79 fellows. The majority of attending physicians and fellows responding to the survey agree that understanding tumor (95% attending physicians; 95% fellows) and germline (86% attending physicians; 94% fellows) genomic information is essential for their practice. However, only 9 of 31 (29%) responding programs report that they have an existing cancer genomics curriculum. Most program directors indicated that the ideal genomics curriculum would occur during the first year of fellowship and incorporate direct patient care, online modules, and problem-based learning. Attending physicians and fellows identified that addressing indications for ordering tumor and germline genomic testing, counseling about the risks and benefits of such testing, and interpreting and individualizing clinical management based on tumor and germline results should be included in a future curriculum. CONCLUSION: The results of this study reveal a great need to develop a curriculum that can be offered across PHO fellowship programs to expand knowledge in the area of cancer genomics.
Authors: Liza-Marie Johnson; Jessica M Valdez; Emily A Quinn; April D Sykes; Rose B McGee; Regina Nuccio; Stacy J Hines-Dowell; Justin N Baker; Chimene Kesserwan; Kim E Nichols; Belinda N Mandrell Journal: Cancer Date: 2017-02-13 Impact factor: 6.860
Authors: G Geller; J R Botkin; M J Green; N Press; B B Biesecker; B Wilfond; G Grana; M B Daly; K Schneider; M J Kahn Journal: JAMA Date: 1997-05-14 Impact factor: 56.272
Authors: Neha R Malhotra; Jessica D Smith; Alexandra C Jacobs; Cali E Johnson; Uzer S Khan; Halle B Ellison; Benjamin J Brintz; Morgan M Millar; William G Cloud; Jeffry Nahmias; Kimberly M Hendershot; Brigitte K Smith Journal: Am J Surg Date: 2020-09-28 Impact factor: 2.565
Authors: Lea F Surrey; Suzanne P MacFarland; Fengqi Chang; Kajia Cao; Komal S Rathi; Gozde T Akgumus; Daniel Gallo; Fumin Lin; Adam Gleason; Pichai Raman; Richard Aplenc; Rochelle Bagatell; Jane Minturn; Yael Mosse; Mariarita Santi; Sarah K Tasian; Angela J Waanders; Mahdi Sarmady; John M Maris; Stephen P Hunger; Marilyn M Li Journal: Genome Med Date: 2019-05-28 Impact factor: 11.117